An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Reyvow

Chemical Namelasmiditan
Dosage FormTablet (oral; 50 mg, 100 mg)
Drug ClassReceptor agonists
SystemNervous
CompanyEli Lilly and Company
Approval Year2020

Indication

  • Reyvow is indicated for the acute treatment of migraine with or without aura in adults.
Last updated on 2/2/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Reyvow (lasmiditan) Prescribing Information 2020Eli Lilly And Co
Document TitleYearSource
Lasmiditan for the acute treatment of migraine. 2020CADTH
Document TitleYearSource
Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis. 2020The Journal of Headache and Pain
Lasmiditan for acute treatment of migraine in adults: a systematic review and meta-analysis of randomized controlled trials.2020CNS Drugs